There’s a wealth of anecdotal evidence that marijuana has medicinal properties, but there’s no actual clinical proof.
And without that all-important clinical proof, most doctors won’t prescribe cannabis-based medications – and insurance companies surely won’t reimburse patients who use them.
The plant we know as marijuana or cannabis isn’t a single plant. It’s actually three closely related, but distinctly different, species. And these species have been cross-bred to create more than 700 marijuana strains.
Each of these 700 strains has varying combinations of the 100 or so naturally occurring chemicals (called cannabinoids) that give cannabis its medicinal properties.
Sorting through combinations of these 100 cannabinoids in the 700-plus marijuana strains could take 15 to 20 years and cost about $800 million using standard research methodology.
Its “fast track” approach is the brainchild of a three-man research team that used it to create Brinavess,® an atrial fibrillation drug (which was licensed to Merck in a deal worth as much as $600 million), as well as drugs for the treatment of asthma, COPD, and cystic fibrosis.
All told, these research superstars have used their fast track methodology to create over $1 billion of shareholder value.
Savvy investors would be well advised to jump in now, because the company is moving forward with the final phase in its research efforts.
And when small-cap and micro-cap companies announce results, their share price can go through the roof. For example…
- Celator Pharmaceuticals went from $1.68 to $9.50 in just one day – a 465% jump!
- Incyte Corp. went from $2.54 to $131 – a 5,057% gain!
- Aquinox Pharmaceuticals rocketed from less than $2.00 to around $21.00 in just two weeks – a staggering gain of over +1,100%!
As I detail in my groundbreaking report, investors could see comparable returns if this company is the first to scientifically prove medical marijuana’s effectiveness.
J. William Roberts, B.S., M.B.A., J.D.
for Investors News Service
P.S. The deep-pocketed strategic partner that recently made a big seven-digit investment in the company is regarded as one of the big players in medical marijuana. In the two years since it went public, it has raised over $22 million, acquired properties for marijuana cultivation and processing in three different states, and obtained (or has conditional applications for) up to 11 cannabis licenses in the US and Canada.
If they’re betting big on this emerging company, that’s a very good sign indeed!
J. William Roberts holds a B.S. in business, magna cum laude, from a prestigious university in New England, an M.B.A. from a highly regarded Mid-Atlantic university, and a J.D. from one of the top law schools in the New York metropolitan area, where he served as a law review editor.
Company Name: PublicWire
Contact Person: Dave Donlin
Email: Send Email
Address:5850 TG Lee Blvd, Suite 300
Country: United States